Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
November 20 2018 - 7:00AM
Business Wire
- Dr. Josep Llovet is a Key Opinion
Leader in the field of liver diseases
- Data from Phase II study in advanced
liver cancer are expected during Q1 2019
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a
biotechnology company with a pipeline of proprietary small molecule
drugs that address cancer, liver and inflammatory diseases,
announced that Professor Josep Llovet, an experienced leader with
deep background in liver cancer research and development, has been
commissioned by the Company to assist in the analysis of the Phase
II data that is anticipated during the first quarter of 2019.
Professor Llovet is Founder and Director of the Liver Cancer
Program and Full Professor of Medicine at the Mount Sinai School of
Medicine, New York University (USA), and Professor of
Research-ICREA in the BCLC Group, Liver Unit, IDIBAPS-Hospital
Clínic, University of Barcelona. Professor Llovet has been
President, Secretary and Founder of the International Liver Cancer
Association (ILCA) and Chairman of the European Clinical Practice
Guidelines of management of liver cancer (EASL-EORTC). A renowned
key opinion leader, Dr. Llovet has published more than 240 articles
in peer-reviewed journals, more than 50 chapters of books, and has
delivered more than 500 lectures. He has devoted the past 20 years
of his career studying the pathogenesis and treatment of liver
cancer.
“We are proud and honored to have the expertise of Prof. Llovet,
who is one of the most distinguished Key Opinion Leaders in the
field of liver diseases, on our team. We look forward to the
insights he will contribute in the analysis of data of our Phase II
advanced liver cancer study when the results are unblinded sometime
during the first quarter of 2019. We believe his depth of
experience both as researcher and as medical practitioner in
treatment of liver cancer will be beneficial to Can-Fite. His
insight and commitment to this field will be quite helpful as we
create a new approach for liver cancer therapy,” stated Can-Fite
CEO Dr. Pnina Fishman.
Due to patient survival, top line efficacy results are expected
during the first quarter of 2019 for Can-Fite’s Phase II clinical
trial of drug candidate Namodenoson (CF102) for the treatment of
advanced hepatocellular carcinoma (HCC) in patients with a Child
Pugh B score whose disease has progressed on sorafenib therapy.
Enrollment of 78 patients was completed in August 2017 and the
trial continues treating subjects in a blinded fashion (either
Namodenoson 25 mg BID or matching placebo). Namodenoson has
received Fast Track Status in the U.S. and Orphan Drug Designation
in Europe and the U.S.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with
high affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated in Phase II trials for two
indications, as a second line treatment for hepatocellular
carcinoma, and as a treatment for non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in
normal cells. This differential effect accounts for the excellent
safety profile of the drug.
About Can-Fite BioPharma
Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, inflammatory disease and sexual
dysfunction. The Company's lead drug candidate, Piclidenoson, is
currently in Phase III trials for rheumatoid arthritis and
psoriasis. Can-Fite's liver cancer drug, Namodenoson, is in Phase
II trials for hepatocellular carcinoma (HCC), the most common form
of liver cancer, and for the treatment of non-alcoholic
steatohepatitis (NASH). Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction in preclinical
studies and the Company is investigating additional compounds,
targeting A3AR, for the treatment of sexual dysfunction. These
drugs have an excellent safety profile with experience in over
1,000 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the initiation, timing, progress and results of our
preclinical studies, clinical trials and other product candidate
development efforts; our ability to advance our product candidates
into clinical trials or to successfully complete our preclinical
studies or clinical trials; our receipt of regulatory approvals for
our product candidates, and the timing of other regulatory filings
and approvals; the clinical development, commercialization and
market acceptance of our product candidates; our ability to
establish and maintain strategic partnerships and other corporate
collaborations; the implementation of our business model and
strategic plans for our business and product candidates; the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
our ability to operate our business without infringing the
intellectual property rights of others; competitive companies,
technologies and our industry; statements as to the impact of the
political and security situation in Israel on our business; and
risks and other risk factors detailed in Can-Fite’s filings with
the SEC and in its periodic filings with the TASE. In addition,
Can-Fite operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors
beyond its control. Can-Fite does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005281/en/
Can-Fite BioPharmaMotti
Farbsteininfo@canfite.com+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024